Atopic dermatitis: a new treatment paradigm using pimecrolimus
Weinberg, J.M.; Bowerman, J.G.; Brown, S.M.; Gerstein, D.; Kane, K.S.; Selevan, J.; Virdee, S.
Journal of Drugs in Dermatology Jdd 2(2): 131-140
2003
ISSN/ISBN: 1545-9616 PMID: 12852364 Document Number: 8330
Atopic dermatitis (AD), often called eczema, is a disease characterized by intense pruritus, erythema, dry skin, and inflammation. Pimecrolimus is a novel steroid-free treatment for AD. Consistently positive results have been found with pimecrolimus treatment in infants, children/adolescents, and adults. Its safety record is excellent, and studies have found no clinically relevant drug-related systemic adverse events. In this article, we first review atopic dermatitis and conventional treatment strategies. We then discuss various aspects of pimecrolimus, including pharmacologic properties, toxicology, short- and long-term studies, and safety and adverse events. Finally, we propose a new steroid-sparing treatment strategy for AD.
Document emailed within 1 workday
